Occurrence of secondary autoimmune disorders and possible risk factors
| Possible risk factors . | Affected by secondary autoimmune disorder, no. . | Unaffected by secondary autoimmune disorder, no. . | P . |
|---|---|---|---|
| Conditioning regimen | |||
| Cy/ATG | 2 | 100 | |
| Cy/alemtuzumab | 4 | 21 | |
| Cy/TBI or Bu/Cy | 0 | 28 | .011 |
| Sex | |||
| Female | 6 | 106 | |
| Male | 0 | 43 | .19 |
| Primary disease | |||
| Systemic lupus erythematosus | 3 | 57 | |
| Multiple sclerosis | 2 | 41 | |
| Systemic sclerosis | 1 | 12 | |
| Crohn disease | 0 | 19 | |
| Rheumatoid arthritis | 0 | 6 | |
| Others | 0 | 14 | ND |
| Type of ATG | |||
| Rabbit | 0 | 51 | |
| Equine | 2 | 49 | .50 |
| PBSC product | |||
| CD34 selected | 2 | 85 | |
| Unmanipulated | 4 | 64 | .41 |
| Possible risk factors . | Affected by secondary autoimmune disorder, no. . | Unaffected by secondary autoimmune disorder, no. . | P . |
|---|---|---|---|
| Conditioning regimen | |||
| Cy/ATG | 2 | 100 | |
| Cy/alemtuzumab | 4 | 21 | |
| Cy/TBI or Bu/Cy | 0 | 28 | .011 |
| Sex | |||
| Female | 6 | 106 | |
| Male | 0 | 43 | .19 |
| Primary disease | |||
| Systemic lupus erythematosus | 3 | 57 | |
| Multiple sclerosis | 2 | 41 | |
| Systemic sclerosis | 1 | 12 | |
| Crohn disease | 0 | 19 | |
| Rheumatoid arthritis | 0 | 6 | |
| Others | 0 | 14 | ND |
| Type of ATG | |||
| Rabbit | 0 | 51 | |
| Equine | 2 | 49 | .50 |
| PBSC product | |||
| CD34 selected | 2 | 85 | |
| Unmanipulated | 4 | 64 | .41 |
Pair-wise comparisons were as follows: Cy/alemtuzumab vs Cy/ATG, P = .014; Cy/alemtuzumab vs Cy/TBI or Bu/Cy, P = .043; and Cy/ATG vs Cy/TBI or Bu/Cy, P > .999.
Cy indicates cyclophosphamide; ATG, antithymocyte globulin; TBI, total body irradiation; Bu, intravenous busulfan; PBSC, peripheral blood stem cell; and ND, not done.